Recent Studies on Design and Development of Drugs Against Alzheimer’s Disease (AD) Based on Inhibition of BACE-1 and Other AD-causative Agents

Author(s): Satya P. Gupta*, Vaishali M. Patil.

Journal Name: Current Topics in Medicinal Chemistry

Volume 20 , Issue 13 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Background: Alzheimer’s disease (AD) is one of the neurodegenerative diseases and has been hypothesized to be a protein misfolding disease. In the generation of AD, β-secretase, γ-secretase, and tau protein play an important role. A literature search reflects ever increasing interest in the design and development of anti-AD drugs targeting β-secretase, γ-secretase, and tau protein.

Objective: The objective is to explore the structural aspects and role of β-secretase, γ-secretase, and tau protein in AD and the efforts made to exploit them for the design of effective anti-AD drugs.

Methods: The manuscript covers the recent studies on design and development of anti-AD drugs exploiting amyloid and cholinergic hypotheses.

Results: Based on amyloid and cholinergic hypotheses, effective anti-AD drugs have been searched out in which non-peptidic BACE1 inhibitors have been most prominent.

Conclusion: Further exploitation of the structural aspects and the inhibition mechanism for β-secretase, γ-secretase, and tau protein and the use of cholinergic hypothesis may lead still more potent anti-AD drugs.

Keywords: Alzheimer's disease, β-secretase, BACE1, γ-secretase, Amyloid precursor protein, tau protein, Anti-AD drugs.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Page: [1195 - 1213]
Pages: 19
DOI: 10.2174/1568026620666200416091623
Price: $65

Article Metrics

PDF: 8